Denali Therapeutics (DNLI) Current Leases (2019 - 2025)
Denali Therapeutics (DNLI) posted quarterly Current Leases of $9.2 million for Q3 2025, up 14.04% year-over-year from $8.0 million in Q3 2024, and up 3.3% quarter-over-quarter from $8.9 million in Q2 2025.
Denali Therapeutics (DNLI) Current Leases (2019 - 2025) Analysis & Trends
Denali Therapeutics (DNLI) has reported Current Leases for 7 consecutive years, with $9.2 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Current Leases rose 14.04% year-over-year to $9.2 million; the TTM figure through Sep 2025 stood at $9.2 million (up 14.04% YoY), while the FY2024 annual figure was $8.3 million, up 14.44% from the prior year.
- Current Leases advanced to $9.2 million in Q3 2025 per DNLI's latest filing, from $8.9 million in the prior quarter.
- Across five years, Current Leases topped out at $9.2 million in Q3 2025 and bottomed at $4.9 million in Q1 2021.
- Historically, Current Leases has averaged $7.0 million across 5 years, with a median of $7.1 million in 2022.
- Annual changes were most pronounced in 2022 — Current Leases soared 34.58% — and 2023, when it retreated 0.79%.
- Denali Therapeutics' Current Leases stood at $5.5 million in 2021, then jumped by 34.2% to $7.3 million in 2022, then dropped by 0.79% to $7.3 million in 2023, then grew by 14.44% to $8.3 million in 2024, then climbed by 10.3% to $9.2 million in 2025.
- Business Quant data shows DNLI's Current Leases at $9.2 million in Q3 2025, $8.9 million in Q2 2025, and $8.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9.16 Mn |
| Jun 30, 2025 | 8.87 Mn |
| Mar 31, 2025 | 8.59 Mn |
| Dec 31, 2024 | 8.31 Mn |
| Sep 30, 2024 | 8.04 Mn |
| Jun 30, 2024 | 7.77 Mn |
| Mar 31, 2024 | 7.51 Mn |
| Dec 31, 2023 | 7.26 Mn |
| Sep 30, 2023 | 7.01 Mn |
| Jun 30, 2023 | 6.77 Mn |
| Mar 31, 2023 | 6.54 Mn |
| Dec 31, 2022 | 7.32 Mn |
| Sep 30, 2022 | 7.07 Mn |
| Jun 30, 2022 | 5.87 Mn |
| Mar 31, 2022 | 5.66 Mn |
| Dec 31, 2021 | 5.45 Mn |
| Sep 30, 2021 | 5.25 Mn |
| Jun 30, 2021 | 5.06 Mn |
| Mar 31, 2021 | 4.88 Mn |
| Dec 31, 2020 | 4.69 Mn |